Obstructive lung disease models: What is valid?

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 5, Issue 6, 2008, Pages 382-393

  Ferdinands, Jill M ^a   Mannino, David M ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Asthma; Chronic obstructive lung disease; Model; Natural history; Validation

Indexed keywords

ASTHMA; BIOLOGICAL MODEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; HUMAN; META ANALYSIS; REVIEW; VALIDATION STUDY;

ASTHMA; HUMANS; MODELS, BIOLOGICAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; VALIDATION STUDIES AS TOPIC;

EID: 65349187280     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412550802522304     Document Type: Review

References (25)

1. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance United States 197-2000.Morbid Mortal Weekly Rept 2002; 51:1-16.
2. Mannino DM, Homa DM, Akinbami LJ, Moorman JE, Gwynn C, Redd SC. Surveillance for Asthma United States, 1980-1999. Morbid Mortal Weekly Report 2002; 51:1-13
3. U.S. Centers for Disease Control and Prevention. Asthma:Gen-eral Information. 4-6-2007. Atlanta, US Centers for Disease Control and Prevention. Report.
4. U.S. Department of Health and Human Services. Facts about Chronic Obstructive Pulmonary Disease (COPD). 4-6-2007. Atlanta, US Centers for Disease Control and Prevention. Report.
5. U.S. Department of Health and Human Services. Healthy People 2010: Understanding and Improving Health, 2nd Ed. 017-001-001-00-550-9. 11-1-2000. Washington DC, US Government Printing Of ce Report.
6. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004; 8:iii-xi,1.
7. Weinstein MC, Toy EL, Sandberg EA, Neumann PJ, Evans JS, Kuntz KM, et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health. 2001; 4:348-361. (Pubitemid 32946233)
8. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johan-nesson M, McCabe C, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices Modeling Studies. Value Health 2003;6:9-17. (Pubitemid 36228345)
9. Buist AS, Vollmer WM, Sullivan SD, Weiss KB, Lee TA, Menezes AM et al. The Burden of Obstructive Lung Disease Initiative (BOLD): rationale and design. COPD J 2005; 2:277-283. (Pubitemid 40993302)
10. Lee TA, Rutten-van Molken MP. Economic modeling in chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society 2006; 3:630-634. (Pubitemid 44411632)
11. Eddy DM. Technology Assessment: The Role of Mathematical Modeling. In: Mosteller F, ed. Assessing Medical Technologies. Washington, DC: National Academy Press; 1985:144-160.
12. Combescure C, Chanez P, Saint-Pierre P, Daures JP, Proudhon H, Godard P. Assessment of variations in control of asthma over time. Eur Respir J 2003; 22:298-304. (Pubitemid 36987001)
13. Fuhlbrigge AL, Bae SJ, Weiss ST, Kuntz KM, Paltiel AD. Cost-effectiveness of inhaled steroids in asthma: impact of effect on bone mineral density. J Allergy Clin Immunol 2006; 117:359-366. (Pubitemid 43192021)
14. Paltiel AD, Fuhlbrigge AL, Kitch BT, Liljas B, Weiss ST, Neumann PJ, et al. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the asthma policy model. J Allergy Clin Immunol 2001; 108:39-46. (Pubitemid 32662230)
15. Price MJ, Briggs AH. Development of an economic model to assess the cost effectiveness of asthma management strategies. Pharmacoeconomics 2002; 20:183-194. (Pubitemid 34454643)
16. Saint-Pierre P, Combescure C, Daures JP, Godard P. The analysis of asthma control under a Markov assumption with use of covariates. Stat Med 2003; 22:3755-3770. (Pubitemid 38008698)
17. Wild DM, Redlich CA, Paltiel AD. Surveillance for isocyanate asthma: a model based cost effectiveness analysis. Occup Environ Med 2005; 62:743-749. (Pubitemid 41565008)
18. Borg S, Ericsson A, Wedzicha J, Gulsvik A, Lundback B, Donaldson GC et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health 2004;7:153-67. (Pubitemid 38420728)
19. Feenstra TL, van Genugten ML, Hoogenveen RT, Wouters EF, Rutten-van Molken MP. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Respir Crit Care Med 2001; 164:590-596. (Pubitemid 32801662)
20. Hoogendoorn M, Rutten-van Molken MP, Hoogenveen RT, van Genugten ML, Buist AS, Wouters EF, et al. A dynamic population model of disease progression in COPD. Eur Respir J 2005; 26:223-233. (Pubitemid 41079065)
21. Johansson PM, Tillgren PE, Guldbrandsson KA, Lindholm LA. A model for cost-effectiveness analyses of smoking cessation interventions applied to a Quit-and-Win contest for mothers of small children. Scand J Public Health 2005; 33:343-352. (Pubitemid 41582345)
22. Oostenbrink JB, Rutten-van Molken MP, Monz BU, FitzGerald JM. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005; 8:32-46. (Pubitemid 40293639)
23. Sin DD, Golmohammadi K, Jacobs P. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am J Med 2004; 116:325-331. (Pubitemid 38230292)
24. Spencer M, Briggs AH, Grossman RF, Rance L. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharma-coeconomics 2005; 23:619-637. (Pubitemid 40994129)
25. Gold MR, JE Siegel, LB Russell, MC Weinstein. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.